ASPCF Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Corp. engages in the development, manufacture, production, marketing, and distribution of women's and men's health products. It focuses on therapeutics for urology, hormone replacement therapy, and female dysfunction. Its products include Estrace, Natesto, Gynoflor, and Tefina. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus, and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.04    OTCQB
As of 01/26/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Industry:  Drug Manufacturers—Specialty &
Index country:  Canada
Country of incorporation:  
IPO date:  11/01/2011
Outstanding shares:  1,537,588,081
Average volume:  48,326
Market cap:   $36,287,079
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   -0.96
PB ratio:   10.00
PS ratio:   -7.89
Return on equity:   171.43%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy